Effect of oral aloe vera powder on type 2 diabetes

Evaluation the Effect of Oral Aloe Vera Administration on Fasting Plasma Glucose, Lipid Profile, Body Composition Components, Anthropometric Indices, and Blood Pressure Values in Patients with Diabetes Type 2

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200331046900N1

Enrollment

Registered

2020-06-24

Start date

2019-01-21

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Type 2 diabetes mellitus without complications

Interventions

Intervention 1: Intervention group: The raw materials and raw materials required were purchased from Shiraz University of Medical Sciences School of Pharmacy with the advice and approval of a consulta

Eligibility

Sex/Gender

All

Age

18 Years to 69 Years

Inclusion criteria

Inclusion criteria: The desire to participate in the study Age range 18 to 69 years Diagnosis of type 2 diabetes by a specialist The minimum duration of type 2 diabetes is 6 months Weight constant over the past 6 months ( Self-report ) The type and dose of medications taken have been stable over the past 6 months

Exclusion criteria

Exclusion criteria: Allergy to aloe vera or products containing it Pregnancy and lactation Use of any dietary supplement in the last 6 months Smoking and addiction Acute heart disease, stroke, liver, kidney, gastrointestinal, thyroid and parathyroid disease, rheumatoid and infectious arthritis

Design outcomes

Primary

Measure	Time frame
Total cholesterol. Timepoint: Before the intervention and after the intervention. Method of measurement: Blood test.	—

Secondary

Measure	Time frame
Fasting blood sugar. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Triglyceride. Timepoint: Before and after the intervention. Method of measurement: Blood test.;High-density lipoprotein. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Low-density lipoprotein. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Anthropometry. Timepoint: Before and after the intervention. Method of measurement: Scales, meters, calipers and .;Blood pressure. Timepoint: Before and after the intervention. Method of measurement: Blood pressure monitor.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Triglyceride. Timepoint: Before and after the intervention. Method of measurement: Blood test.;High-density lipoprotein. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Low-density lipoprotein. Timepoint: Before and after the intervention. Method of measurement: Blood test.;Anthropometry. Timepoint: Before and after the intervention. Method of measurement: Scales, meters, calipers and .;Blood pressure. Timepoint: Before and after the intervention. Method of measurement: Blood pressure monitor.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNajmeh Sadat Zareian Jahromi

Shiraz University of Medical Sciences

najmeh.zareayan@gmail.com+98 71 9101 1710

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026